As US health authorities continue examining the proposed COVID-19 vaccines, residents in the United Kingdom — the first Western country to issue approval for emergency use — are set to receive their first shots as early as this week.
But quickly vaccinating as many people as possible in the U.K. will pose enormous logistical challenges — from keeping the doses frozen to figuring out how to methodically and fairly distribute the vaccine across the nation of 68 million.
The first batch of the vaccine created by Pfizer and the German company BioNTech arrived in the U.K. last week. Doses are scheduled to be delivered to hospitals beginning Monday. Nursing home residents, health care workers and people aged 80 and over will be first in line.
Across England, 50 hospitals have been chosen as hubs to administer the vaccine, the BBC reported. The government has initially ordered 40 million doses, which will vaccinate 20 million people. The National Health Service has said that more hubs will be set up as more doses arrive.
“There’s something like five doses to each vial, and each box is 975 doses,” Sarah Boseley, health editor for The Guardian, told NPR’s Weekend Edition. “Because they’re kept in this deep-frozen state, they then have to be very, very carefully split up. And that is the bit, actually, that hasn’t yet been properly figured out.”
Why is the vaccine all set to be distributed in the U.K., while Americans are still waiting for approval from the Food and Drug Administration? “The FDA in the United States actually demands all the raw details,” Boseley said.
Whereas U.K. health regulators depend on companies’ summaries of their vaccine’s effectiveness, U.S. officials are more hands-on — and warier. “They’re not taking what the companies say as necessarily accurate,” Boseley said. “So they will do their own data analysis and hopefully come up with exactly the same results.”
All that double-checking could add only an extra week or so to the timeline. An FDA advisory panel is scheduled to meet virtually on Thursday to discuss whether to approve the vaccine for emergency use. (Source: npr.org)